Keros Therapeutics adopts poison pill and launches strategic review including potential sale

Keros Therapeutics, Inc.

Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.
Adopted limited-duration rights plan (10% threshold, 15% for passive institutional) expiring April 9, 2026.
Rights plan triggered by an individual investor that disclosed 11.2% ownership as of April 6, 2025.
Dividend of one right per common share for stockholders of record on April 24, 2025.
Goldman Sachs & Co. LLC engaged as financial advisor; Cooley LLP as legal counsel.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Keros Therapeutics, Inc.: Certificate of Designations establishing Preferred Shares filed with Delaware Secretary of State (effective 2025-04-09).

Change: charter amendment
Effective: 2025-04-09

Exact text from the filing

the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on April 9, 2025.

View on SEC.gov

Browse all governance changes →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-25-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.